Loss of Glyoxalase 1 Induces Compensatory Mechanism to Achieve Dicarbonyl Detoxification in Mammalian Schwann Cells*

The glyoxalase system is a highly specific enzyme system existing in all mammalian cells that is responsible for the detoxification of dicarbonyl species, primarily methylglyoxal (MG). It has been implicated to play an essential role in preventing the increased formation of advanced glycation end products under certain pathological conditions. We have established the first glyoxalase 1 knock-out model (GLO1−/−) in mammalian Schwann cells using the CRISPR/Cas9 technique to investigate compensatory mechanisms. Neither elevated concentrations of MG nor associated protein modifications were observed in GLO1−/− cells. Alternative detoxification of MG in GLO1−/− is achieved by increased catalytic efficiency of aldose reductase toward hemithioacetal (product of glutathione and MG), which is most likely caused by S-nitrosylation of aldose reductase. The hemithioacetal is mainly converted into lactaldehyde, which is paralleled by a loss of reduced glutathione. Inhibition of aldose reductase in GLO1−/− cells is associated with an increased sensitivity against MG, elevated intracellular MG levels, associated modifications, as well as increased oxidative stress. Our data suggest that aldose reductase can compensate for the loss of GLO1. This might be of clinical importance within the context of neuronal diseases caused by an impaired glyoxalase system and elevated levels of dicarbonyl species, such as MG.

[1]  D. Böckler,et al.  Reduced glyoxalase 1 activity in carotid artery plaques of nondiabetic patients with increased hemoglobin A1c level. , 2016, Journal of vascular surgery.

[2]  Paul J Thornalley,et al.  Improved Glycemic Control and Vascular Function in Overweight and Obese Subjects by Glyoxalase 1 Inducer Formulation , 2016, Diabetes.

[3]  R. Petersen,et al.  Metabolic Dysfunction Is Restricted to the Sciatic Nerve in Experimental Diabetic Neuropathy , 2015, Diabetes.

[4]  P. Magistretti,et al.  Methylglyoxal, the dark side of glycolysis , 2015, Front. Neurosci..

[5]  Paul J Thornalley,et al.  Measurement of methylglyoxal by stable isotopic dilution analysis LC-MS/MS with corroborative prediction in physiological samples , 2014, Nature Protocols.

[6]  Jiankun Cui,et al.  Proteomic Quantification and Site-Mapping of S-Nitrosylated Proteins Using Isobaric iodoTMT Reagents , 2014, Journal of proteome research.

[7]  A. Hidmark,et al.  A new paradigm to understand and treat diabetic neuropathy. , 2014, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[8]  Gangyi Yang,et al.  Efficacy and Safety of Aldose Reductase Inhibitor for the Treatment of Diabetic Cardiovascular Autonomic Neuropathy: Systematic Review and Meta-Analysis , 2014, PloS one.

[9]  G. Yetik-Anacak,et al.  Methylglyoxal causes endothelial dysfunction: the role of endothelial nitric oxide synthase and AMP-activated protein kinase α , 2014, Journal of basic and clinical physiology and pharmacology.

[10]  Paul J Thornalley,et al.  Detection of oxidized and glycated proteins in clinical samples using mass spectrometry--a user's perspective. , 2014, Biochimica et biophysica acta.

[11]  K. Sango,et al.  Physiological and Pathological Roles of Aldose Reductase in Schwann Cells , 2014 .

[12]  Paul J Thornalley,et al.  The Critical Role of Methylglyoxal and Glyoxalase 1 in Diabetic Nephropathy , 2013, Diabetes.

[13]  V. D’Agati,et al.  Knockdown of Glyoxalase 1 Mimics Diabetic Nephropathy in Nondiabetic Mice , 2013, Diabetes.

[14]  Lixin Liu,et al.  Methylglyoxal modulates endothelial nitric oxide synthase-associated functions in EA.hy926 endothelial cells , 2013, Cardiovascular Diabetology.

[15]  A. Bierhaus,et al.  Association of reduced glyoxalase 1 activity and painful peripheral diabetic neuropathy in type 1 and 2 diabetes mellitus patients. , 2013, Journal of diabetes and its complications.

[16]  J. Milbrandt,et al.  Aberrant Schwann Cell Lipid Metabolism Linked to Mitochondrial Deficits Leads to Axon Degeneration and Neuropathy , 2013, Neuron.

[17]  Chankyu Park,et al.  Human DJ-1 and its homologs are novel glyoxalases. , 2012, Human molecular genetics.

[18]  Rendy Kartika,et al.  Exploring post-translational arginine modification using chemically synthesized methylglyoxal hydroimidazolones. , 2012, Journal of the American Chemical Society.

[19]  Paul J Thornalley,et al.  Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy , 2012, Nature Medicine.

[20]  Paul J Thornalley,et al.  Transcriptional control of glyoxalase 1 by Nrf2 provides a stress-responsive defence against dicarbonyl glycation. , 2012, The Biochemical journal.

[21]  Joachim Goedhart,et al.  Structure-guided evolution of cyan fluorescent proteins towards a quantum yield of 93% , 2012, Nature Communications.

[22]  Pierre J Magistretti,et al.  Role of the Glyoxalase System in Astrocyte-Mediated Neuroprotection , 2011, The Journal of Neuroscience.

[23]  D. Wright,et al.  Characterisation of glyoxalase I in a streptozocin-induced mouse model of diabetes with painful and insensate neuropathy , 2011, Diabetologia.

[24]  C. Stehouwer,et al.  Overexpression of Glyoxalase-I Reduces Hyperglycemia-induced Levels of Advanced Glycation End Products and Oxidative Stress in Diabetic Rats* , 2010, The Journal of Biological Chemistry.

[25]  Kate E Schemmel,et al.  Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review. , 2010, Journal of diabetes and its complications.

[26]  A. Bhatnagar,et al.  Reductive Metabolism of AGE Precursors: A Metabolic Route for Preventing AGE Accumulation in Cardiovascular Tissue , 2009, Diabetes.

[27]  A. Bhatnagar,et al.  Posttranslational glutathiolation of aldose reductase (AKR1B1): a possible mechanism of protein recovery from S-nitrosylation. , 2009, Chemico-biological interactions.

[28]  M. A. Ramirez,et al.  Epalrestat: An Aldose Reductase Inhibitor for the Treatment of Diabetic Neuropathy , 2008, Pharmacotherapy.

[29]  A. Bhatnagar,et al.  Role of Nitric Oxide in Regulating Aldose Reductase Activation in the Ischemic Heart* , 2008, Journal of Biological Chemistry.

[30]  Su-Yen Goh,et al.  The role of advanced glycation end products in progression and complications of diabetes , 2008 .

[31]  N. Toltl,et al.  Quantitation of acetol in common pharmaceutical excipients using LC-MS. , 2008, Journal of pharmaceutical and biomedical analysis.

[32]  A. Bhatnagar,et al.  The Aldo-Keto Reductase Superfamily and its Role in Drug Metabolism and Detoxification , 2008, Drug metabolism reviews.

[33]  E. Randell,et al.  Plasma methylglyoxal and glyoxal are elevated and related to early membrane alteration in young, complication-free patients with Type 1 diabetes , 2007, Molecular and Cellular Biochemistry.

[34]  Irfan Rahman,et al.  Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method , 2006, Nature Protocols.

[35]  Paul J Thornalley,et al.  Peptide Mapping Identifies Hotspot Site of Modification in Human Serum Albumin by Methylglyoxal Involved in Ligand Binding and Esterase Activity* , 2005, Journal of Biological Chemistry.

[36]  Lingyun Wu,et al.  Methylglyoxal-induced nitric oxide and peroxynitrite production in vascular smooth muscle cells. , 2005, Free radical biology & medicine.

[37]  Paul J Thornalley Glyoxalase I--structure, function and a critical role in the enzymatic defence against glycation. , 2003, Biochemical Society transactions.

[38]  Anne Dawnay,et al.  Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. , 2003, The Biochemical journal.

[39]  D. V. Vander Jagt,et al.  Methylglyoxal metabolism and diabetic complications: roles of aldose reductase, glyoxalase-I, betaine aldehyde dehydrogenase and 2-oxoaldehyde dehydrogenase. , 2003, Chemico-biological interactions.

[40]  M. Brownlee Insight Review Articles , 2022 .

[41]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[42]  D. V. Vander Jagt,et al.  Metabolism of the 2-oxoaldehyde methylglyoxal by aldose reductase and by glyoxalase-I: roles for glutathione in both enzymes and implications for diabetic complications. , 2001, Chemico-biological interactions.

[43]  L. Beilin,et al.  Advanced glycation end-products: a review , 2001, Diabetologia.

[44]  Paul J Thornalley,et al.  Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. , 1999, The Biochemical journal.

[45]  S. Watowich,et al.  Structural and kinetic determinants of aldehyde reduction by aldose reductase. , 1999, Biochemistry.

[46]  G. Izaguirre,et al.  Methylglyoxal as substrate and inhibitor of human aldehyde dehydrogenase: comparison of kinetic properties among the three isozymes. , 1998, Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology.

[47]  Paul J Thornalley,et al.  Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. , 1998, The Journal of clinical investigation.

[48]  Paul J Thornalley,et al.  Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. , 1994, Clinical science.

[49]  Paul J Thornalley,et al.  Modification of the glyoxalase system in streptozotocin-induced diabetic rats. Effect of the aldose reductase inhibitor Statil. , 1993, Biochemical pharmacology.

[50]  D. V. Vander Jagt,et al.  Reduction of trioses by NADPH-dependent aldo-keto reductases. Aldose reductase, methylglyoxal, and diabetic complications. , 1992, The Journal of biological chemistry.

[51]  Paul J Thornalley,et al.  Synthesis of 14C‐labelled methylglyoxal and S‐D‐lactoylglutathione , 1990 .

[52]  C. Rae,et al.  Kinetic analysis of the human erythrocyte glyoxalase system using 1H NMR and a computer model. , 1990, European journal of biochemistry.

[53]  Paul J Thornalley The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life. , 1990, The Biochemical journal.

[54]  Paul J Thornalley,et al.  Glyoxalase activity in human red blood cells fractioned by age , 1989, Mechanisms of Ageing and Development.

[55]  F. Denizot,et al.  Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. , 1986, Journal of immunological methods.

[56]  T. Kern,et al.  Immunohistochemical distribution of aldose reductase , 1982, The Histochemical Journal.

[57]  M. M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[58]  A. Mizisin Mechanisms of diabetic neuropathy: Schwann cells. , 2014, Handbook of clinical neurology.

[59]  Ding Wen-long The Mechanisms of the Diabetic Neuropathy , 2005 .

[60]  Paul J Thornalley The glyoxalase system in health and disease. , 1993, Molecular aspects of medicine.

[61]  D. Dolphin,et al.  Glutathione : chemical, biochemical, and medical aspects , 1989 .

[62]  I. Carlberg,et al.  Glutathione reductase. , 1985, Methods in enzymology.

[63]  B. Mannervik,et al.  [59] Glutathione reductase , 1985 .

[64]  Thomas D. Schmittgen,et al.  Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2 2 DD C T Method , 2022 .